You searched for "Tumours"
Papilloedema: an update
1 June 2016
| James F (Barry) Cullen
|
EYE - Neuro-ophthalmology
Some readers may have seen a recent report in the national newspapers of the case of a teenage girl with persistent severe headache associated with a fatal brain tumour having been undiagnosed despite many consultations with her medical advisers. It...
A prospective trial of adjuvant therapy for high-risk melanoma
Patients diagnosed with iris, ciliary body or choroidal melanoma of high-risk tumour cytogenetics (monosomy 3>/= 20% of cells), were treated with adjuvant low-dose dacarbacine (DTIC) and interferon –alpha-2b (IFNA-2b), following primary treatment (enucleation, brachytherapy or resection). DTIC was given intravenously...Systemic screening in adnexal lymphoma
This is a retrospective review of 119 patients diagnosed with ocular adnexal lymphoma, 85 of whom had primary adnexal disease and 34 had previously been diagnosed with lymphoma outside the ocular adnexa. Sixty-eight of the primary and 24 of the...Outcomes of plaque radiotherapy for retinoblastoma
The study authors evaluate their experience of plaque radiotherapy for retinoblastoma (RB) in 41 eyes of 41 patients that failed intra-arterial chemotherapy (IAC). This was a retrospective review including 21 females and 20 males. Median age was 18 months and...Atlas Of Orbital Imaging
It was an absolute pleasure to review this beautifully written textbook. Authorship is from a diverse, international group of experienced and respected oculoplastic surgeons with an interest in orbital disease. A significant contribution to most of these chapters has been...High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Conjunctival mapping biopsies in sebaceous carcinoma
This is a retrospective review of conjunctival mapping biopsies in patients with periocular sebaceous cell carcinoma. The authors reviewed the biopsy technique and outcomes of 45 patients who had mapping biopsies performed over a 25-year period. A total of 429...Virtual reality is revolutionising healthcare
From mental health therapies to surgical training, virtual reality is revolutionising healthcare, finds GlobalData.Retinoblastoma – the challenges of a rare cancer and the role of international partnerships
4 October 2023
| Richard Bowman, Mattan Arazi, Aniruddh Heroor, Kahaki Kimani, M Ashwin Reddy, Ido Didi Fabian, Swathi Kaliki
|
EYE - Paediatrics, EYE - Strabismus
Introduction: the global challenge The global burden of retinoblastoma (Rb) is one in 15,000-18,000 live births, which equates to 8000 new cases worldwide each year. The global disparities in Rb outcome represent a paradigm of health inequality worldwide [1]. In...
Quiz Oct/Nov 2024
History An 83-year-old female was previously treated by surgical excision and plaque brachytherapy for her left conjunctival lesion. She presented to her ophthalmologist with a recurrence some years later and underwent a lid sparing orbital exenteration, which was sent to...Nanoparticle administration of latanoprost
1 December 2013
| Graham Wallace
|
EYE - Glaucoma
Glaucoma is a progressive optic neuropathy characterised by increased ocular pressure and loss of retinal ganglion cells. Conventional drug therapy with eye drops to reduce intraocular pressure (IOP) has variable bioavailability and can lead to ocular surface disease. In this...
Practice patterns of uveal melanoma management with Iodine-125 brachytherapy
5 August 2020
| Annes Ahmeidat
|
EYE - Pathology, EYE - Oncology
|
Brachytherapy, Treatment practices, Uveal melanoma
With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....